SMS Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 31 May 2025
Result Summary
- SMS Pharmaceuticals Ltd reported a 41.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 64.2%.
- Its expenses for the quarter were up by 47.5% QoQ and 61.2% YoY.
- The net profit decreased 5.3% QoQ and increased 177.8% YoY.
- The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 247.44 | 175.48 | 150.68 | 41.0% | 64.2% |
Total Expenses | 225.71 | 153.04 | 140.05 | 47.5% | 61.2% |
Profit Before Tax | 21.74 | 22.44 | 10.63 | -3.1% | 104.5% |
Tax | 5.69 | 5.36 | 2.57 | 6.2% | 121.4% |
Profit After Tax | 17.28 | 18.24 | 6.22 | -5.3% | 177.8% |
Earnings Per Share | 2.00 | 2.10 | 0.70 | -4.8% | 185.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
SMS Pharmaceuticals Ltd is a pharmaceutical company primarily engaged in the development, manufacture, and sale of active pharmaceutical ingredients (APIs). The company operates within the pharmaceutical industry, which is characterized by significant research and development activities, stringent regulatory requirements, and a strong emphasis on innovation and product efficacy. SMS Pharmaceuticals Ltd focuses on producing high-quality generic drugs and APIs, contributing to the broader healthcare sector's goal of providing accessible and cost-effective medication. The company has been involved in several collaborations and partnerships to enhance its research capabilities and market reach. Recent developments include expansion into new therapeutic areas and markets, although specific details of these initiatives are not provided in the data.
Revenue
During Q4FY25, SMS Pharmaceuticals Ltd reported a total income of ₹247.44 crores, marking a significant increase of 41.0% compared to the previous quarter (Q3FY25), where the total income was ₹175.48 crores. This growth is even more pronounced when compared year-over-year (YoY) to Q4FY24, where the total income was ₹150.68 crores, representing a 64.2% increase. The company's revenue growth can be attributed to various factors, possibly including increased sales volume, introduction of new products, or expansion into new markets, although specific details are not provided in the data.
Profitability
In Q4FY25, the profit before tax for SMS Pharmaceuticals Ltd was ₹21.74 crores, showing a slight decline of 3.1% from the previous quarter's figure of ₹22.44 crores. However, when looking at the year-over-year change, there is a significant increase of 104.5% from Q4FY24, where the profit before tax was ₹10.63 crores. The profit after tax for Q4FY25 was ₹17.28 crores, which represents a decrease of 5.3% from Q3FY25's ₹18.24 crores but an impressive 177.8% increase from ₹6.22 crores in Q4FY24. Earnings per share (EPS) in Q4FY25 stood at ₹2.00, reflecting a decrease of 4.8% from the previous quarter's EPS of ₹2.10, yet a 185.7% increase from ₹0.70 in Q4FY24. This data highlights substantial year-over-year growth in profitability metrics.
Operating Metrics
Total expenses for SMS Pharmaceuticals Ltd in Q4FY25 were reported at ₹225.71 crores, which is a 47.5% increase from Q3FY25's expenses of ₹153.04 crores. This is also a 61.2% rise compared to ₹140.05 crores in Q4FY24. The tax expense for the quarter was ₹5.69 crores, marking an increase of 6.2% from Q3FY25's tax of ₹5.36 crores, and a 121.4% increase from ₹2.57 crores in Q4FY24. The company's financial performance exhibits a substantial rise in both income and expenses, reflecting dynamic operational activities and possibly strategic investments or expansions, although specific reasons are not detailed in the provided data.